By Cecilia Butini

Bayer AG said Wednesday that its heart-failure treatment, Verquvo, was granted marketing authorization in the European Union.

The German conglomerate said the treatment, also known as vericiguat, is for patients with chronic heart failure who have suffered a worsening in their condition.

Verquvo is already approved in the U.S. and Japan. Marketing authorization for the drug has been submitted in China and other countries world-wide, Bayer said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

July 21, 2021 07:13 ET (11:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bayer Aktiengesellschaft (PK) Charts.